Kinetics of viral load and antibody response in relation to COVID-19 severity
- 1 October 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (10) , 5235-5244
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for coronavirus 2019 (COVID-19) pneumonia. Little is known about the kinetics, tissue distribution, cross-reactivity, and neutralization antibody response in patients with COVID-19. Two groups of patients with RT-PCR–confirmed COVID-19 were enrolled in this study: 12 severely ill patients in intensive care units who needed mechanical ventilation and 11 mildly ill patients in isolation wards. Serial clinical samples were collected for laboratory detection. Results showed that most of the severely ill patients had viral shedding in a variety of tissues for 20–40 days after onset of disease (8/12, 66.7%), while the majority of mildly ill patients had viral shedding restricted to the respiratory tract and had no detectable virus RNA 10 days after onset (9/11, 81.8%). Mildly ill patients showed significantly lower IgM response compared with that of the severe group. IgG responses were detected in most patients in both the severe and mild groups at 9 days after onset, and remained at a high level throughout the study. Antibodies cross-reactive to SARS-CoV and SARS-CoV-2 were detected in patients with COVID-19 but not in patients with MERS. High levels of neutralizing antibodies were induced after about 10 days after onset in both severely and mildly ill patients which were higher in the severe group. SARS-CoV-2 pseudotype neutralization test and focus reduction neutralization test with authentic virus showed consistent results. Sera from patients with COVID-19 inhibited SARS-CoV-2 entry. Sera from convalescent patients with SARS or Middle East respiratory syndrome (MERS) did not. Anti–SARS-CoV-2 S and N IgG levels exhibited a moderate correlation with neutralization titers in patients’ plasma. This study improves our understanding of immune response in humans after SARS-CoV-2 infection.Keywords
Funding Information
- the national key Research and Development Program of China (The National Key Research, Development Program of China)
- the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology (2020YFC0841400)
- Guangdong Province Basic and Applied Basic Research Fund (2020A1515010911)
This publication has 22 references indexed in Scilit:
- Epidemiology, Genetic Recombination, and Pathogenesis of CoronavirusesTrends in Microbiology, 2016
- Detection of the Human Coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, JapanJapanese Journal of Infectious Diseases, 2015
- Characterization of Human Coronavirus OC43 and Human Coronavirus NL63 Infections Among Hospitalized Children <5 Years of AgeThe Pediatric Infectious Disease Journal, 2014
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012
- Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan PopulationClinical and Vaccine Immunology, 2008
- The Novel Human Coronaviruses NL63 and HKU1Journal of Virology, 2007
- Croup Is Associated with the Novel Coronavirus NL63PLOS Medicine, 2005
- Antigenic Cross‐Reactivity between Severe Acute Respiratory Syndrome–Associated Coronavirus and Human Coronaviruses 229E and OC43The Journal of Infectious Diseases, 2005
- The Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003
- The Morphology of Three Previously Uncharacterized Human Respiratory Viruses that Grow in Organ CultureJournal of General Virology, 1967